StreetInsider.com News Articles

BMO Capital Starts Trevi Therapeutics (TRVI) at Outperform

Mon, 20 Jul 2026 17:01:56 -0400

(Updated - July 20, 2026 5:01 PM EDT)

BMO Capital analyst Connor Murphy initiates coverage on Trevi Therapeutics (NASDAQ: TRVI) with a Outperform rating, PT $36.00.

The analyst comments "We initiate coverage of Trevi Therapeutics with an Outperform rating and $36 target. Our positive view is based on: 1) Haduvio’s potentially first-in-class opportunity in IPF-related chronic cough, supported by clean Phase 2b CORAL data; 2) a differentiated central-plus-peripheral mechanism that may support best-in-class efficacy; 3) a coherent franchise strategy across IPF-CC, nonIPF ILD-CC, and refractory chronic cough; and 4) a defined late-stage development path, strong IP position, and balance sheet that support

BMO Capital Starts Trevi Therapeutics (TRVI) at Outperform

Mon, 20 Jul 2026 17:01:56 -0400

(Updated - July 20, 2026 5:01 PM EDT)

BMO Capital analyst Connor Murphy initiates coverage on Trevi Therapeutics (NASDAQ: TRVI) with a Outperform rating, PT $36.00.

Trevi Therapeutics (TRVI) PT Raised to $31 at B.Riley

Mon, 20 Jul 2026 08:35:22 -0400

B.Riley analyst Mayank Mamtani raised the price target on Trevi Therapeutics (NASDAQ: TRVI) to $31.00 (from $21.00) while maintaining a Buy rating.

Trevi Therapeutics (TRVI) PT Raised to $24 at H.C. Wainwright

Mon, 20 Jul 2026 06:48:54 -0400

(Updated - July 20, 2026 6:48 AM EDT)

H.C. Wainwright analyst Brandon Folkes raised the price target on Trevi Therapeutics (NASDAQ: TRVI) to $24.00 (from $21.00) while maintaining a Buy rating.

The analyst commented: "GSK’s decision not to progress camlipixant in refractory chronic cough, or RCC, was surprising given the earlier clinical data, but we view the announcement as a significant net positive for TRVI. We previously expected camlipixant to establish the RCC market, raise physician and patient awareness, and create a meaningful population of non-responders and partial responders who could ultimately move to Haduvio, and thus saw positives in a situation

Trevi Therapeutics (TRVI) PT Raised to $24 at H.C. Wainwright

Mon, 20 Jul 2026 06:48:54 -0400

(Updated - July 20, 2026 6:48 AM EDT)

H.C. Wainwright analyst Brandon Folkes raised the price target on Trevi Therapeutics (NASDAQ: TRVI) to $24.00 (from $21.00) while maintaining a Buy rating.

Trevi Therapeutics (TRVI) PT Raised to $40 at Clear Street

Mon, 20 Jul 2026 05:28:07 -0400

Clear Street analyst Kaveri Pohlman raised the price target on Trevi Therapeutics (NASDAQ: TRVI) to $40.00 (from $29.00) while maintaining a Buy rating.

Trevi Therapeutics Announces Upcoming June and July Event Schedule

Wed, 17 Jun 2026 07:30:00 -0400

NEW HAVEN, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will attend several upcoming events in June and July.

BIO International Convention
June 22-25, 2026, San Diego, California
Trevi Representatives: Jennifer Good, President and CEO, and Farrell Simon, Pharm.D., CCO

Leerink Partners Therapeutics Forum 2026
July 14-15, 2026, Boston, Massachusetts
Trevi Representatives: David Hastings, CFO, and Farrell Simon, Pharm.D., CCO

ERS Cough

Trevi Therapeutics Announces Upcoming June and July Event Schedule

Wed, 17 Jun 2026 07:30:00 -0400

NEW HAVEN, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will attend several upcoming events in June and July.

BIO International Convention
June 22-25, 2026, San Diego, California
Trevi Representatives: Jennifer Good, President and CEO, and Farrell Simon, Pharm.D., CCO

Leerink Partners Therapeutics Forum 2026
July 14-15, 2026, Boston, Massachusetts
Trevi Representatives: David Hastings, CFO, and Farrell Simon, Pharm.D., CCO

ERS Cough

Trevi Therapeutics Announces Upcoming June and July Event Schedule

Wed, 17 Jun 2026 07:30:00 -0400

NEW HAVEN, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will attend several upcoming events in June and July.

BIO International Convention
June 22-25, 2026, San Diego, California
Trevi Representatives: Jennifer Good, President and CEO, and Farrell Simon, Pharm.D., CCO

Leerink Partners Therapeutics Forum 2026
July 14-15, 2026, Boston, Massachusetts
Trevi Representatives: David Hastings, CFO, and Farrell Simon, Pharm.D., CCO

ERS Cough

Trevi Therapeutics Announces Upcoming June and July Event Schedule

Wed, 17 Jun 2026 07:30:00 -0400

NEW HAVEN, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will attend several upcoming events in June and July.

BIO International Convention
June 22-25, 2026, San Diego, California
Trevi Representatives: Jennifer Good, President and CEO, and Farrell Simon, Pharm.D., CCO

Leerink Partners Therapeutics Forum 2026
July 14-15, 2026, Boston, Massachusetts
Trevi Representatives: David Hastings, CFO, and Farrell Simon, Pharm.D., CCO

ERS Cough

Form 4 Trevi Therapeutics, Inc. For: Jun 03 Filed by: Mathers Edward T

Thu, 04 Jun 2026 16:28:00 -0400
si-local-file:///var/storage/secattach/20260604/26606124.html

Form 4 Trevi Therapeutics, Inc. For: Jun 03 Filed by: Mathers Edward T

Thu, 04 Jun 2026 16:28:00 -0400
si-local-file:///var/storage/secattach/20260604/26606124.html

Form 4 Trevi Therapeutics, Inc. For: Jun 03 Filed by: VANLENT ANNE

Thu, 04 Jun 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260604/26605561.html

Form 4 Trevi Therapeutics, Inc. For: Jun 03 Filed by: VANLENT ANNE

Thu, 04 Jun 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260604/26605561.html

Form 4 Trevi Therapeutics, Inc. For: Jun 03 Filed by: Heffernan Michael Thomas

Thu, 04 Jun 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260604/26605566.html

Form 4 Trevi Therapeutics, Inc. For: Jun 03 Filed by: Heffernan Michael Thomas

Thu, 04 Jun 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260604/26605566.html

Form 4 Trevi Therapeutics, Inc. For: Jun 03 Filed by: Meeker David P

Thu, 04 Jun 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260604/26605567.html

Form 4 Trevi Therapeutics, Inc. For: Jun 03 Filed by: Meeker David P

Thu, 04 Jun 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260604/26605567.html

Form 4 Trevi Therapeutics, Inc. For: Jun 03 Filed by: Colangelo Dominick

Thu, 04 Jun 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260604/26605574.html

Form 4 Trevi Therapeutics, Inc. For: Jun 03 Filed by: Colangelo Dominick

Thu, 04 Jun 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260604/26605574.html

Form 8-K Trevi Therapeutics, Inc. For: Jun 03

Thu, 04 Jun 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260604/26605580.html

Form 8-K Trevi Therapeutics, Inc. For: Jun 03

Thu, 04 Jun 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260604/26605580.html

Trevi Therapeutics (TRVI) PT Raised to $30 at Stifel

Fri, 08 May 2026 08:43:41 -0400
Stifel analyst Annabel Samimy raised the price target on Trevi Therapeutics (NASDAQ: TRVI) to $30.00 (from $18.00) while maintaining a Buy rating.

Form SCHEDULE 13D/A Trevi Therapeutics, Inc. Filed by: New Enterprise Associates 16, L.P.

Thu, 07 May 2026 18:23:00 -0400
si-local-file:///var/storage/secattach/20260507/26455660.html

Form SCHEDULE 13D/A Trevi Therapeutics, Inc. Filed by: New Enterprise Associates 16, L.P.

Thu, 07 May 2026 18:23:00 -0400
si-local-file:///var/storage/secattach/20260507/26455660.html